Atlas Trials

Bortezomib and Low Dose Cytarabine in the Treatment of High-risk Myelodysplastic Syndromes

Clinical trial NCT00411905 · COMPLETED

Trial details

NCT number
NCT00411905
Sponsor
Groupe Francophone des Myelodysplasies
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Myelodysplastic Syndromes
Start date
2006-06-01
Primary completion
2010-07-08
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.